Anti-LAG3 antibodies and uses thereof
US11692032B2 · kind B2 · utility
0Cited by
12References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2019 |
| Grant date | Jul 4, 2023 |
| Priority date | — |
| Expiry date | Jul 3, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.